London
· Delayed Price · Currency is GBP · Price in GBXOxford Biomedica Company Description
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.
Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems.
The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties.
The Product segment is involved in the research and development of new gene therapeutic product candidates.
The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types.
The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996.
Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.
| Country | United Kingdom |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 703 |
| CEO | Frank Mathias |
Contact Details
Address: Windrush Court Oxford, OX4 6LT United Kingdom | |
| Phone | 44 1865 783 000 |
| Website | oxb.com |
Stock Details
| Ticker Symbol | OXB |
| Exchange | London Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| ISIN Number | GB00BDFBVT43 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Frank Mathias | Chief Executive Officer and Director |
| Dr. Lucinda Crabtree Ph.D. | Chief Financial Officer and Director |
| Thierry Cournez | Chief Operating Officer |
| Sophia Bolhassan | Head of Investor Relations |
| Natalie Louise Walter | General Counsel and Company Secretary |
| Lisa Doman | Chief People Officer |
| Dr. Kyriacos Mitrophanous Ph.D. | Chief Innovation Officer |
| Kati Hudson | Head of Intellectual Property and Contracts |
| Dr. Sebastien Ribault | Chief Business Officer |
| Mark Caswell | Site Head of UK Operations |